For research use only. Not for therapeutic Use.
Clamikalant sodium (HMR 1098) is an ATP-sensitive potassium (KATP) channel blocker. Clamikalant sodium can be used for the research of arrhythmia[1].
Clamikalant sodium (HMR 1098; 40 μM) prevents improvement effect of Levosimendam on left ventricular developed pressure (LVDP) recovery rate, abolishes the inhibitory effect of Levosimendan on hypothermic preservation-induced activation of calpain, cleavage of Bid, and apoptosis[2].
Clamikalant sodium (HMR 1098; 30 µM, 24 hours) reduces cellular viability, increases the apoptosis of Neonatal rat cardiomyocytes (NRCs) [3].
Clamikalant sodium (30 µM) decreases the Bcl-2 protein level and increases the Bax protein level in the LPS-exposed NRCs[3].
Clamikalant sodium (HMR 1098; 6.0 mg/kg; 5 min prior to EET administration) completely abolishes the cardioprotection produced by epoxyeicosatrienoic acid (EET)[1].
| Catalog Number | I045071 |
| CAS Number | 261717-22-0 |
| Synonyms | sodium;(5-chloro-2-methoxybenzoyl)-[2-[4-methoxy-3-(methylcarbamothioylsulfamoyl)phenyl]ethyl]azanide |
| Molecular Formula | C19H21ClN3NaO5S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H22ClN3O5S2.Na/c1-21-19(29)23-30(25,26)17-10-12(4-6-16(17)28-3)8-9-22-18(24)14-11-13(20)5-7-15(14)27-2;/h4-7,10-11H,8-9H2,1-3H3,(H3,21,22,23,24,29);/q;+1/p-1 |
| InChIKey | SUEVHDKFEXAKAF-UHFFFAOYSA-M |
| SMILES | CNC(=S)NS(=O)(=O)C1=C(C=CC(=C1)CC[N-]C(=O)C2=C(C=CC(=C2)Cl)OC)OC.[Na+] |
| Reference | [1]. Garrett J Gross, et al. Roles of endothelial nitric oxide synthase (eNOS) and mitochondrial permeability transition pore (MPTP) in epoxyeicosatrienoic acid (EET)-induced cardioprotection against infarction in intact rat hearts. J Mol Cell Cardiol. 2013 Ju [2]. Hai-yan Zhou, et al. Improved myocardial function with supplement of levosimendan to Celsior solution. J Cardiovasc Pharmacol. 2014 Sep;64(3):256-65. [3]. Xiaohui Zhang, et al. Sarcolemmal ATP-sensitive potassium channel protects cardiac myocytes against lipopolysaccharide-induced apoptosis. Int J Mol Med. 2016 Sep;38(3):758-66. |
